Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

Ardelyx (NASDAQ: ARDX) shares closed at $4.00 on August 7, 2026, an 17.86% single-session decline, after the Company reported second quarter 2026 product revenue of $118.1 million and a loss of approximately $(0.07) per share -- both below consensus estimates. Investors who suffered losses on ARDX are encouraged to request a review of your ARDX losses.

The quarterly breakdown released after the close on August 6, 2026 showed IBSRELA product revenue of $86.2 million and XPHOZAH product revenue of $31.9 million. Alongside the results, Ardelyx lowered its full-year 2026 IBSRELA revenue guidance to $350 million to $370 million from $410 million to $430 million, and are reassessing the timing of its long-term $1 billion revenue target for IBSRELA. Analyst reaction followed immediately with multiple covering firms cutting their price targets following the release and the stock fell nearly 18%.

An investigation is pending into potential securities law violations on behalf of Ardelyx shareholders. Shareholders who lost money on Ardelyx stock may have their losses evaluated at no cost.

Shares fell approximately 17.86%, a decline of roughly $0.87 per share, closing at $4.00 on August 7, 2026 after the Company reported second quarter results below consensus and lowered its full-year 2026 IBSRELA revenue guidance. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Investors who purchased ARDX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

An investigation is being conducted into potential securities fraud claims on behalf of investors who purchased ARDX securities.

Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices are needed to participate.

Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ARDX and sold at a loss may still participate in the investigation.

There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court.